Search results
Results from the WOW.Com Content Network
Brexpiprazole, sold under the brand name Rexulti among others, is an atypical antipsychotic medication used for the treatment of major depressive disorder, schizophrenia, and agitation associated with dementia due to Alzheimer's disease. [11] [13] [14] The most common side effects include akathisia (a constant urge to move) and weight gain. [12]
This is a list of investigational obsessive–compulsive disorder drugs, or drugs that are currently under development for clinical use in the treatment of obsessive–compulsive disorder (OCD) but are not yet approved. Chemical/generic names are listed first, with developmental code names, synonyms, and brand names in parentheses.
This is a list of psychiatric medications used by psychiatrists and other physicians to treat mental illness or distress. The list is ordered alphabetically according to the condition or conditions, then by the generic name of each medication. The list is not exhaustive and not all drugs are used regularly in all countries.
In 2006, the FDA required manufacturers to add a black box warning to the label, warning that older people who were given the drug for dementia-related psychosis were at greater risk of death. [121] In 2007, aripiprazole was approved by the FDA for the treatment of unipolar depression when used adjunctively with an antidepressant medication. [4]
Samidorphan (INN Tooltip International Nonproprietary Name, USAN Tooltip United States Adopted Name) is an opioid antagonist that in the form of olanzapine/samidorphan (sold as Lybalvi) is used in the treatment of schizophrenia and bipolar disorder.
Lurasidone was first approved for medical use in the United States in 2010. [2] In 2013, it was approved in Canada and by the U.S. Food and Drug Administration (FDA) to treat bipolar depression, either as monotherapy or adjunctively with lithium or valproate.
In 2005, the FDA issued an advisory warning of an increased risk of death when atypical antipsychotics are used in dementia. [47] In the subsequent 5 years, the use of atypical antipsychotics to treat dementia decreased by nearly 50%. [47] As of now, the only FDA-approved atypical antipsychotic for alzheimer-related dementia is brexpiprazole.
Fluvoxamine, sold under the brand name Luvox among others, is an antidepressant of the selective serotonin reuptake inhibitor (SSRI) class. [8] It is primarily used to treat major depressive disorder and, perhaps more-especially, obsessive–compulsive disorder (OCD), [9] but is also used to treat anxiety disorders [10] such as panic disorder, social anxiety disorder, and post-traumatic stress ...